Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Sep 25, 2022; 11(5): 391-393
Published online Sep 25, 2022. doi: 10.5501/wjv.v11.i5.391
Possible agent for COVID-19 treatment: Rifampicin
Ozlem Celik Aydin, Sonay Aydın, Sureyya Barun
Ozlem Celik Aydin, Department of Medical Pharmacology, Erzincan University, Mengucek Gazi Education and Research Hospital, Erzincan 24100, Turkey
Sonay Aydın, Sureyya Barun, Department of Pharmacology, Gazi University, Ankara 06500, Turkey
Sonay Aydın, Department of Radiology, Erzincan University, Erzincan 24100, Turkey
Author contributions: Aydın S, Aydin OC and Barun S conceived the study; Aydın S, Aydin OC and Barun S were responsible for designing, materials and supervision; Aydın S, Aydin OC and Barun S did the literature search, wrote the manuscript, and reviewed the manuscript critically; All authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ozlem Celik Aydin, MD, Doctor, Department of Medical Pharma-cology, Erzincan University, Mengucek Gazi Education and Research Hospital, Başbağlar Mahallesi Hacı Ali Akın Caddesi No. 32 Erzincan/Merkez, Erzincan 24100, Turkey. ozlemclk_89@hotmail.com
Received: April 20, 2022
Peer-review started: April 20, 2022
First decision: June 8, 2022
Revised: June 20, 2022
Accepted: August 25, 2022
Article in press: August 25, 2022
Published online: September 25, 2022
Processing time: 156 Days and 14.6 Hours
Abstract

Rifampicin is a promising drug for the treatment of coronavirus disease 2019 based on its antiviral properties and recent in silico studies. In silico studies can serve as a foundation for further studies.

Keywords: Rifampicin; COVID-19; Treatment; In silico; Drug-drug interaction; Therapeutic potential

Core Tip: Rifampicin may be used as a treatment for coronavirus disease 2019 (COVID-19). Although it has a variety of drug-drug interactions, none of the important ones for the currently utilised COVID-19 medicines, favipiravir, enoxaparin, and aspirin, have been defined.